[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100053796":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":12,"centralContacts":7,"locations":16,"responsibleParty":30,"collaborators":7,"id":32,"slug":33,"hasResults":34,"nctId":35,"briefTitle":36,"officialTitle":36,"acronym":7,"eligibilityCriteria":37,"healthyVolunteers":34,"sex":38,"minAge":39,"maxAge":7,"enrollmentInfo":40,"targetDuration":7,"studyType":42,"phases":43,"briefSummary":45,"conditions":46,"keywords":49,"overallStatus":60,"whyStopped":7,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":7,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},{"fullName":5,"class":6},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH",null,[9],{"type":10,"name":11,"description":7,"armGroupLabels":7,"otherNames":7},"DRUG","Pentamidine isethionate",[13],{"name":14,"affiliation":7,"role":15},"Smaldone G","STUDY_CHAIR",[17],{"facility":18,"status":7,"city":19,"state":20,"zip":21,"country":22,"countryCode":23,"cosmosGeoPoint":24,"geoPoint":29,"contacts":7},"SUNY - Stony Brook","Stony Brook","New York","11794","United States","US",{"type":25,"coordinates":26},"Point",[27,28],-73.14094,40.92565,{"lat":28,"lon":27},{"type":31,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100053796","aerosols-in-the-treatment-of-asymptomatic-pneumocystis-pneumonia-a-pilot-study-assessing-the-effectiveness-of-aerosolized-pentamidine-as-treatment-of-subclinical-pneumocystis-infection-in-patients-with-no-clinical-symptoms-100053796",false,"NCT00000707","Aerosols in the Treatment of Asymptomatic Pneumocystis Pneumonia: A Pilot Study Assessing the Effectiveness of Aerosolized Pentamidine as Treatment of Subclinical Pneumocystis Infection in Patients With No Clinical Symptoms","Inclusion Criteria\n\nConcurrent Treatment:\n\nAllowed during aerosolization:\n\nMetaproterenol or albuterol to treat bronchospasm.\n\nPatients must have:\n\n* HIV infection confirmed by ELISA, HIV culture, or p24 antigenemia.\n* Suspected subclinical Pneumocystis carinii infection as detected by \\> 10 percent change in lung volumes and\u002For diffusing capacity indicative of progressive restrictive disease as detected by monthly screening pulmonary function tests (PFT's). Patients will be afebrile and have no respiratory signs or symptoms of clinical disease. Morphologic confirmation of pneumocysts will be determined by bronchoalveolar lavage (BAL) performed 24 hours after the initial aerosol inhalation. If the BAL is negative for pneumocysts, the patient will be withdrawn from this protocol and will be followed per the screening PFT protocol at Stony Brook.\n* Diagnostic bronchoscopy and BAL must be performed within 2 weeks of detection of \\> 10 percent change in PFTs.\n* Ability and willingness to sign informed consent.\n\nPrior Medication:\n\nAllowed:\n\n* Primary prophylaxis with agents active against Pneumocystis carinii pneumonia (PCP), but no more than 5 patients may have received prior prophylaxis with aerosolized pentamidine.\n* Zidovudine.\n\nExclusion Criteria\n\nCo-existing Condition:\n\nPatients with the following conditions or symptoms are excluded:\n\n* History of Pneumocystis carinii pneumonia (PCP).\n* Development of respiratory signs and\u002For symptoms in the interval between detection of pulmonary function test (PFT) abnormality and the time of initial aerosol deposition.\n* Dyspnea, cough, or bronchospasm that prevents cooperation with aerosol administration.\n* History of a major adverse reaction to pentamidine defined by absolute neutropenia, \\\u003C 750 polymorphonuclear leukocytes plus bands; thrombocytopenia, \\\u003C 40000 platelets; creatinine rise, \\> 3.0 mg\u002Fdl; liver function abnormalities, SGOT or SGPT \\> 5 x normal; hypoglycemia, \\\u003C 50 mg\u002Fdl; rash, exfoliative or mucositis; cough, unremitting cough or bronchospasm uncontrolled by bronchodilator preventing \\> 50 percent of dose delivered for \\> 2 days.\n\nConcurrent Medication:\n\nExcluded:\n\n* Zidovudine.\n\nPatients unable to cooperate with aerosol administration are excluded.\n\nPrior Medication:\n\nExcluded:\n\n\\- Another antiprotozoal regimen for this episode. Unable to complete therapy or follow-up for social reasons in the opinion of the investigator.","ALL","13 Years",{"count":41,"type":7},20,"INTERVENTIONAL",[44],"NA","To confirm the ability of pulmonary (lung) function testing (PFT) to detect Pneumocystis carinii pneumonia (PCP) before the development of clinical symptoms and to determine if pentamidine (PEN), a drug used in treating PCP, can be given effectively as an aerosol (inhaled mist). Other goals include the measurement of the actual amount of PEN that reaches the lung, and to determine if close clinical observation is safer and as effective as drug therapy for the prevention of subsequent episodes of PCP.\n\nMany AIDS patients develop PCP, but the effectiveness of early diagnosis and treatment of PCP is not known. The effectiveness of PEN may be improved if treatment is begun when the parasite burden (the number of organisms in the lung) is still small, and before respiratory symptoms appear. If PFT of HIV-infected patients is able to identify patients in the early stages of infection, outpatient treatment of these patients offers a possible alternative to the expense and toxicity of continuous preventive therapy of all high-risk patients.",[47,48],"Pneumonia, Pneumocystis Carinii","HIV Infections",[50,51,52,53,54,55,56,57,58,59],"Respiratory Function Tests","AIDS-Related Opportunistic Infections","Pneumonia, Pneumocystis carinii","Pentamidine","Lung","HIV Seropositivity","Drug Evaluation","Administration, Inhalation","Aerosols","Acquired Immunodeficiency Syndrome","COMPLETED","2021-10-26",{"date":63,"type":64},"2021-11-02","ACTUAL",{"date":66,"type":64},"1991-06",{"name":5,"class":6},1]